Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11078
Title: Liver regeneration and tumour stimulation: implications of the renin-angiotensin system.
Authors: Koh, Shir Lin;Ager, Eleanor I;Christophi, Christopher
Affiliation: Austin Health, Department of Surgery, The University of Melbourne, Heidelberg, Vic., Australia. shir_lin@hotmail.com
Issue Date: 1-Nov-2010
Citation: Liver International : Official Journal of the International Association For the Study of the Liver; 30(10): 1414-26
Abstract: Liver resection is the most effective treatment for primary liver tumours and metastasis to the liver, and remains the only potentially long-term curative therapy for patients with colorectal cancer (CRC) liver metastases. Nevertheless, there is a significant incidence of tumour recurrence following liver resection. Cellular and molecular changes resulting from resection and the subsequent liver regeneration process may influence the kinetics of tumour growth, contributing to recurrence. Although commonly associated with the systemic homeostasis of blood pressure, fluid and electrolyte, the renin-angiotensin system (RAS) has recently been shown to play a role in regulating cell proliferation, apoptosis and angiogenesis in local organs as well as in malignancies. An electronic search of the English literature on the role of the RAS in liver regeneration and tumourigenesis was performed using PubMed, with additional relevant articles sourced from reference lists. Studies have shown that the blockade of the RAS pathway stimulates liver regeneration and inhibits tumour progression. An understanding of the role of RAS in liver regeneration and tumourigenesis may enable alternative strategies to improve patient outcome and survival after liver resection. This review will discuss the role of the RAS in liver regeneration and in tumour recurrence post-liver resection. The potential of the RAS as a novel therapeutic target for CRC liver metastases patients undergoing liver resection will be outlined.
Internal ID Number: 20633100
URI: http://ahro.austin.org.au/austinjspui/handle/1/11078
DOI: 10.1111/j.1478-3231.2010.02306.x
URL: http://www.ncbi.nlm.nih.gov/pubmed/20633100
Type: Journal Article
Subjects: Angiotensin II Type 1 Receptor Blockers.therapeutic use
Angiotensin-Converting Enzyme Inhibitors.therapeutic use
Animals
Antineoplastic Agents.therapeutic use
Cell Proliferation.drug effects
Chemotherapy, Adjuvant
Hepatectomy.adverse effects
Humans
Liver.drug effects.metabolism.pathology.surgery
Liver Neoplasms.drug therapy.metabolism.pathology.surgery
Liver Regeneration.drug effects
Neoplasm Recurrence, Local.etiology.metabolism.pathology.prevention & control
Renin-Angiotensin System.drug effects
Treatment Outcome
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.